Sub-Navigation

• Investor News
• Ad-hoc Publications
• Press
• Archive
  • Overview
  • Investor News 2011
  • Investor News 2010
  • Investor News 2009
  • Investor News 2008
  • Investor News 2007
  • Investor News 2006
  • Investor News 2005
  • Investor News 2004
  • Investor News 2003
  • Investor News 2002
  • Investor News 2001
  • Investor News 2000
  • Ad-hoc 2011
  • Ad-hoc 2010
  • Ad-hoc 2009
  • Ad-hoc 2008
  • Ad-hoc 2007
  • Ad-hoc 2006
  • Ad-hoc 2005
  • Ad-hoc 2004
  • Ad-hoc 2003
  • Ad-hoc 2002
  • Ad-hoc 2001
  • Ad-hoc 2000
  • Ad-hoc 1999
  • Ad-hoc 1998

Bayer Links

• Bayer Global
• Sustainability
• Press
• Bayer in Social Media

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• News
• Archive
• Investor News 2011

Search

Here you find Investor News of year 2011. Ad-hoc messages issued in year 2011 can be found here.
Publications of the previous years are offered in the Archive Overview.

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

Receive our IR News via E-Mail, RSS Feed or SMS.

Thursday December 29, 2011

Not intended for U.S. and UK Media - Submission in New Indication:

Bayer's Xarelto® (Rivaroxaban) Submitted for U.S. Marketing Authorisation to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

Thursday December 22, 2011

Not intended for U.S. and UK media: Acute Coronary Syndrome (ACS):

Bayer's Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for Secondary Prevention after an Acute Coronary Syndrome

Submission based on positive results of ATLAS ACS 2-TIMI 51 study / Xarelto is the only new oral anticoagulant to demonstrate significant clinical benefit in this indication when used in combination with standard antiplatelet therapy

Tuesday December 20, 2011

Bayer: Four potential blockbusters in the Pharma pipeline

Good prospects for Xarelto

Monday December 19, 2011

For use outside the US and UK only

Bayer's Xarelto® Approved in the EU for the Prevention of Stroke in Patients with AF and in the Treatment of DVT

In stroke prevention in AF, Xarelto is the only oral anticoagulant offering patients a once-daily, highly effective therapy without need for routine coagulation monitoring / For the treatment of DVT and the prevention of recurrent DVT and PE, Xarelto is the first oral anticoagulant to offer patients both efficacy and the convenience of a single-drug solution, without the need for injections or monitoring / Xarelto is now approved in the EU across three indications in the area of venous and arterial thromboembolism (VAT)

Thursday December 15, 2011

Settlement agreements with U.S. long-grain rice growers have taken effect

Wednesday December 14, 2011

For use outside the US and UK only

New Intrauterine System for long-term contraception submitted for marketing authorization both in the EU and the U.S.

Once approved, the new low dose IUS will offer young women contraception for up to three years

Friday December 09, 2011

Not intended for U.S. and UK media: Bayer's drospirenone-containing combination oral contraceptives:

FDA Advisory Committees affirm positive benefit-risk profile and recommend an update of US labels to reflect information from available studies

Tuesday December 06, 2011

Company streamlines its crop protection portfolio further:

Bayer CropScience divests Rovral® and Sportak® fungicides to FMC

Monday November 28, 2011

Not intended for U.S. and UK Media

Bayer and Regeneron Initiate Phase III Clinical Trial for the Treatment of Wet Age-Related Macular Degeneration in China

Wednesday November 16, 2011

"Perspective on Growth in Asia"

Bayer plans further expansion in Asia

Sales in the region to grow to well over EUR 11 billion by 2015 / Some EUR 6 billion in sales expected in Greater China alone / Plans to expand production, distribution network and research / Further capital expenditures of EUR 1.8 billion in Asia by 2015 / New TDI production facility dedicated in Shanghai

Sunday November 13, 2011

Not intended for U.S. and UK Media: Secondary Prevention of Acute Coronary Syndrome (ACS):

Bayer's Xarelto® (Rivaroxaban) Meets Primary Efficacy Endpoint and Shows Significant Reduction in Mortality in Major ACS Study

Rivaroxaban Meets Primary Efficacy Endpoint, Significantly Reducing the Composite of Cardiovascular Death, Myocardial Infarction and Stroke / Rivaroxaban 2.5 mg twice daily Significantly Reduced Both the Rate of Cardiovascular Death and the Incidence of All-Cause Mortality by more than 30% / Major Bleeding in Patients Receiving Rivaroxaban was Significantly Increased but there was no Increase in the Risk of Fatal Bleeding / Study Results Presented as a Late-Breaker at the Scientific Sessions of the American Heart Association and Published by the New England Journal of Medicine

Friday November 04, 2011

Not intended for U.S. and UK Media - Stroke Prevention in Patients with Atrial Fibrillation:

US FDA Approves Bayer's Xarelto® (Rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

Rivaroxaban is highly effective and well tolerated in protecting patients with Atrial Fibrillation from stroke / Rivaroxaban is the only anticoagulant with once-daily fixed dosing for stroke prevention in patients with atrial fibrillation / Rivaroxaban does not require routine coagulation monitoring, making it more convenient to both patients and physicians

Thursday October 27, 2011

Bayer MaterialScience sells Viverso to Nuplex Industries

Thursday October 27, 2011

After a good third quarter: Bayer confirms Group outlook

Sales up by 4.8 percent (adjusted) to EUR 8,670 million / Continuing growth momentum in the emerging markets (adjusted: plus 9.5 percent) / Operating result (EBIT) increased by 94.9 percent to EUR 1,099 million / EBITDA before special items up by 8.5 percent to EUR 1,805 million / HealthCare and CropScience margins distinctly improved - MaterialScience weaker / Net income more than doubled to EUR 642 million (plus 125.3 percent)

Wednesday October 26, 2011

Not intended for U.S. and UK media

Phase III Trial of Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival

Trial stopped based on positive data from a pre-planned interim analysis

Wednesday October 12, 2011

Not intended for U.S. and UK media

Bayer HealthCare and Onyx Pharmaceuticals Restructure Global Oncology Partnership

Settlement in Litigation Reached

Friday October 07, 2011

New Oilseed varieties and breeding material:

Bayer CropScience strengthens seed platform in Europe through acquisition of the Raps GbR oilseed rape business

Accelerated entry into the European oilseed rape market

Friday October 07, 2011

Not intended for U.S. and UK media: Secondary Prevention of Acute Coronary Syndrome:

Phase III Study of Bayer's Rivaroxaban in Patients with Acute Coronary Syndrome Accepted for Presentation as Late Breaker at AHA Scientific Sessions 2011

Full results of Phase III ATLAS ACS 2 TIMI 51 clinical trial to be presented on November 13, 2011

Saturday September 24, 2011

Not intended for U.S. and UK Media: Results of Phase III study in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases:

Positive Phase III Data on Bayer's Investigational Drug Alpharadin Show Significant Increase in Overall Survival

First presentation of full data as part of Presidential Session featuring best and late-breaking abstracts at 2011 European Multidisciplinary Cancer Congress

Friday September 23, 2011

Not intended for U.S. and UK media

Xarelto® Recommended for Approval in the Prevention of AF Related Stroke and Treatment of Deep Vein Thrombosis in EU

CHMP recommends approval of rivaroxaban for two new chronic indications / Upon approval, rivaroxaban would be the only new oral anticoagulant approved in three indications in all EU member states / Decision of European Commisson on approval expected in fourth quarter 2011

Thursday September 15, 2011

Propelling growth across the value-chain from seed-to-shelf:

Bayer CropScience presents new four pillar growth strategy: Focus on portfolio conversion, value chain, BioScience and innovation

Investment in BioScience research to double by 2015 / Accelerated portfolio conversion: Phase-out of WHO Class I products by end of 2012

Tuesday September 13, 2011

Not intended for U.S. and UK Media

Bayer and Onyx Announce New Nexavar® Data To Be Presented at the 2011 ECCO-ESMO Congress

Tuesday September 13, 2011

Not intended for U.S. and UK Media

Bayer to Present New Data Evaluating Investigational Oncology Compounds at 2011 ECCO-ESMO Congress

Full results of Phase III Alpharadin trial being presented in Presidential Session I: Best and Late Breaking Abstracts / Phase II trial results evaluating Regorafenib in multiple tumor types

Friday September 09, 2011

Not intended for U.S. and UK Media - Stroke Prevention in Patients with Atrial Fibrillation:

U.S. FDA Advisory Committee Recommends Approval of Bayer's Xarelto® (Rivaroxaban)

Tuesday September 06, 2011

Not intended for U.S. and UK Media - Stroke Prevention in Patients with Atrial Fibrillation:

Bayer Confident in Results of ROCKET AF Study to be Reviewed by the FDA Cardiovascular and Renal Drugs Advisory Committee

Thursday September 01, 2011

Bayer Healthcare to acquire Pathway Medical Technologies

Transaction complements business portfolio in vascular intervention technologies

Tuesday August 23, 2011

Not intended for U.S. Media

FDA Grants Fast Track Designation to Bayer's Investigational Compound Alpharadin (TM) for the Treatment of Castration Resistant Prostate Cancer in Patients with Bone Metastases

Thursday July 28, 2011

Interim report for the second quarter of 2011:

Bayer continues positive momentum

Sales up 5.4 percent on an adjusted basis to EUR 9,252 million / Operating result (EBIT) advances 25.9 percent to EUR 1,273 million / EBITDA before special items increases by 5.8 percent to EUR 2,035 million / Net income rises by substantial 40.9 percent to EUR 747 million / Group outlook for 2011 confirmed / Significant progress with innovation projects / Efficiency measures advancing well

Wednesday July 27, 2011

Not intended for U.S. and UK media

Bayer and Trius Therapeutics to develop and commercialize new antibiotic for specific skin infections and pneumonia

Monday July 25, 2011

Not intended for U.S. and UK Media

Phase III J-ROCKET AF Study of Bayer's Xarelto® (rivaroxaban) Meets Primary Endpoint

Safety of once-daily Xarelto comparable to warfarin in Japanese patients with atrial fibrillation / Results presented in the late breaking clinical trials session at the 23rd Congress of the International Society on Thrombosis and Haemostasis in Kyoto, Japan / As communicated in April 2011, Xarelto has been submitted for marketing approval in the prevention of stroke in patients with atrial fibrillation to the Japanese Ministry of Health, Labor and Welfare

Friday July 08, 2011

Not intended for U.S. Media

European Patent Office decides on Yasmin® patent challenge

Saturday July 02, 2011

Bayer CropScience Settles Biotech Rice Litigation

Friday July 01, 2011

Not intended for U.S. and UK Media

FDA Approves Xarelto® (rivaroxaban tablets) for the Prophylaxis of Deep Vein Thrombosis Which May Lead to a Pulmonary Embolism in Patients Undergoing Knee or Hip Replacement Surgery

Xarelto® is the only new oral anticoagulant with US approval in this indication

Wednesday June 29, 2011

Not intended for U.S. and UK Media

VEGF Trap-Eye Submitted for Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration in Japan

Tuesday June 07, 2011

Not intended for U.S. and UK media

VEGF Trap-Eye Submitted for EU Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration

Monday June 06, 2011

Not intended for U.S. Media

Alpharadin Significantly Improves Overall Survival in Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone

Trial Stopped Based on Positive Data from Pre-Planned Interim Analysis / Patients on Placebo Arm will be Offered Treatment with Alpharadin

Wednesday May 25, 2011

Not intended for U.S. and UK media - ROCKET AF, the landmark double-blind study of rivaroxaban versus warfarin:

Major Subgroup Analysis Shows Bayer's Rivaroxaban is Highly Effective in the Prevention of Recurrent Strokes

Positive benefit-risk profile of rivaroxaban in secondary prevention patients, a group who are difficult to manage and who experience the greatest complications from current anticoagulation therapy, including intra-cranial haemorrhage (ICH)

Thursday May 19, 2011

Not intended for U.S. and UK Media

Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase II Study

Wednesday May 18, 2011

Not intended for U.S. and UK Media

Nexavar Data in Multiple Tumor Types To Be Presented at 2011 American Society of Clinical Oncology Annual Meeting (ASCO)

Wednesday May 18, 2011

Not intended for U.S. and UK Media

Bayer to Present Data on Oncology Portfolio at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)

Presentations highlight Bayer's growing oncology pipeline

Friday April 29, 2011

Bayer CEO Dr. Marijn Dekkers at the Bayer AG Annual Stockholders' Meeting:

"Our goal is to make Bayer a world-class innovative company"

Group targets achieved in 2010 / Proposal to raise dividend for 2010 to EUR 1.50 per share / Successful start to 2011 with sales and earnings gains in all subgroups / Investment for the future planned to total EUR 15 billion through 2013

Thursday April 28, 2011

First quarter of 2011: all subgroups lift sales and earnings

Bayer off to a successful start to 2011

Sales up by 13.2 percent to EUR 9,415 million / Operating result (EBIT) rises by 4.0 percent to EUR 1,148 million / EBITDA before special items advances by 22.3 percent to EUR 2,232 million / Special items of EUR 442 million diminish earnings / Net income up 8.4 percent to EUR 684 million / Group forecast raised - improvement expected at CropScience

Wednesday April 27, 2011

Not intended for U.S. Media

Bayer and Regeneron Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion

Phase 3 GALILEO study confirms results of previously announced Phase 3 COPERNICUS study

Friday April 15, 2011

Bayer MaterialScience raises prices for polyurethane raw materials in Europe

Thursday April 14, 2011

Not intended for U.S. Media - Stroke Prevention in Patients with Atrial Fibrillation:

Bayer's Rivaroxaban Submitted for Approval in Japan

Friday April 08, 2011

Not intended for U.S. Media

Bayer and Regeneron Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema

Extends ophthalmology research & development program for VEGF Trap-Eye

Tuesday April 05, 2011

Not intended for U.S. Media - Prevention of VTE in hospitalized, acutely ill patients:

In the Prevention of VTE in Acutely ill Patients, Rivaroxaban Compares Favorably with Enoxaparin but Does Not Show a Consistent Net Clinical Benefit

MAGELLAN study meets primary efficacy endpoints of demonstrating non-inferiority in short-term use and superiority in long-term use / Primary analysis shows no consistent positive benefit-risk balance across heterogeneous patient population studied

Wednesday March 23, 2011

Expansion and investment in southern US soybean seed market:

Bayer CropScience to acquire US-based Hornbeck Seed Company

Tuesday March 15, 2011

Not intended for U.S. Media

U.S. FDA Approves Bayer's Gadobutrol Injection for MRI of the Central Nervous System

Monday February 28, 2011

Financial News Conference on fiscal 2010:

Bayer: operating performance on track

Group targets achieved / Strong year at MaterialScience - HealthCare and CropScience below expectations / Net income diminished by high special charges / Strong operating cash flow - net financial debt below EUR 8 billion / Confidence for 2011: core earnings per share expected to improve by about 10 percent / About EUR 15 billion investment for the future planned through 2013 / Proportion of female managers to grow toward 30 percent by 2015

Thursday February 24, 2011

Bayer proposes dividend increase to EUR 1.50 per share for 2010

Monday January 31, 2011

Focus on more growth and innovation

Organizational changes at Bayer HealthCare

Streamlining administration, strengthening research and development / Handover in management of Consumer Care Division / Site consolidation at the U.S. East Coast

Friday January 28, 2011

Bayer and Zydus Cadila sign Joint Venture Agreement to strengthen pharmaceutical business in India

Tuesday January 18, 2011

Not intended for U.S. Media: VEGF Trap-Eye in myopic choroidal neovascularization:

Bayer and Regeneron start clinical Phase III trial to extend ophthalmology research & development program for VEGF Trap-Eye in Asia

Collaboration with the Singapore Eye Research Institute to tackle a major eye disease common in Asia

Monday January 10, 2011

Not intended for U.S. Media

Bayer Initiates Phase III Trial of Regorafenib in Metastatic or Unresectable Gastrointestinal Stromal Tumors

Monday January 10, 2011

First Patients enrolled in EU Phase III Clinical Development Progam to evaluate ATX-101 for Reduction of Submental Fat

Bayer's dermatology unit Intendis one step closer to enter aesthetics segment / Joint development of first-in-class injectable drug for minimally invasive facial fat reduction

Wednesday January 05, 2011

For use outside the U.S. only

Bayer's Rivaroxaban Submitted for Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation in the US

Wednesday January 05, 2011

For use outside the U.S. only

Bayer's Rivaroxaban Submitted for EU Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation as well as for the Treatment of Deep Vein Thrombosis (DVT) and Prevention of Recurrent DVT and Pulmonary Embolism (PE)

Submission in Stroke Prevention in Patients with Atrial Fibrillation (AF) based on positive results of ROCKET AF trial in more than 14,000 patients / Submission in Treatment of DVT and Prevention of Recurrent DVT and PE based on positive results of EINSTEIN-DVT and EINSTEIN-Extension clinical studies in more than 4,500 patients